CRX100

Cell therapy

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Colorectal Cancer · Phase 1Hepatocellular Carcinoma · Phase 1Ovarian Cancer · Phase 1Gastric Cancer · Phase 1Melanoma · Phase 1

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Non-Small Cell Lung Cancer

Competitive landscape

This drug's own stage for Colorectal Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CRX100: this drugPhase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.